Pharmaceutical Microbiology Market size is expected to reach USD 18 Billion by the end of 2036, growing at a CAGR of 9% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of pharmaceutical microbiology was over USD 6 Billion. The market for pharma microbiology is primarily driven by the rise in the prevalence of infectious disorders. Infectious diseases such as sexually transmitted infections (STDs), HIV, and infectious diseases like hepatitis A, B, and C are becoming more commonplace worldwide. For instance, globally 39 million people [33.1 million-45.7 million] were HIV positive in 2022. The market for pharma microbiology is therefore driven by the rising number of infectious illness cases brought on by contaminated needle injections, unprotected sex, homelessness, lack of access to healthcare, and other socioeconomic difficulties.
Furthermore, regulatory agencies such as the FDA and EMA, have stringent guidelines mandating the sterility of pharmaceutical products to ensure patient safety. Compliance with these regulations necessitates throughout the manufacturing process, driving the demand for microbiology services and products. Also, maintaining sterility is essential for preserving the efficacy and safety of pharmaceutical products. Therefore, these factors are accelerating the growth of the market.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
~ 9% |
|
Base Year Market Size (2023) |
~ USD 6 Billion |
|
Forecast Year Market Size (2036) |
~ USD 18 Billion |
|
Regional Scope |
|
Product Type (Pharmaceutical, Biopharmaceutical)
The biopharmaceutical segment in the pharmaceutical microbiology market is expected to grow with the largest share of 54% during the forecast period. As biopharmaceuticals are made using living microbes and animal cells, they have a high therapeutic value and can effectively cure a wide range of chronic illnesses, including diabetes, cancer, cardiovascular disease, Parkinson's disease, and many more. Furthermore, as the worldwide geriatric population ages and becomes more susceptible to chronic illnesses, the need for biologic medications is expected to rise. Also, pharmaceutical companies are investing heavily in the research and development of biological drugs, leading to an expanding pipeline of innovative therapies targeting various diseases. For instance, the US Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) introduced by Novartis to treat moderate to severe hidradenitis suppurative (HS) in adults. The only fully human biologic licensed by the FDA that directly inhibits interleukin-17A (IL-17A), a cytokine thought to be implicated in HS inflammation, is Cosentyx.2.
Service (Microbial Identification, Antimicrobial Effectiveness, Stability Studies, Validation of Microbial Recovery, Minimum Inhibitory Concentration (MIC) Evaluations, Minimum Bactericidal Concentration (MBC) Evaluations)
Pharmaceutical Microbiology Market for the microbial identification segment is expected to hold a share of 35% by the end of 2036. With the expanding complexity of pharmaceutical manufacturing processes and the worldwide nature of supply chains, pharmaceutical companies are increasingly concerned about microbial contamination. As a result, there is a growing emphasis on microbiological identification to detect and treat contamination issues promptly, ensuring product quality and safety. Furthermore, technological advancements have resulted in the development and acceptance of rapid microbiological techniques (RMM) for microbial identification, which is expected to rise further in the future. Furthermore, the advent of new microbial diseases is also propelling the growth of the segment. Some microbial diseases include tuberculosis, Lyme disease, measles, malaria, fungal diseases, and others. According to the most recent estimates, there are 476,000 new Lyme cases in the United States each year, and is expected to increase by 59% by 2021. Scientists predict that two million people will suffer from post-treatment Lyme disease by the end of 2020. Microbial identification is critical for tracking and characterizing these infections to establish effective control measures and treatment plans.
Our in-depth analysis of the global market includes the following segments:
|
Type |
|
|
Services |
|
|
Tests |
|
|
End-user |
|
North American Market Forecast
The North American pharmaceutical microbiology market is poised to account for the largest share of 36% during the forecast period. Due to its better health care system and stringent regulations, the region has a higher demand for pharmaceutical microbiology products. Moreover, innovation in testing technologies is encouraged by the existence of large research and development, biotechnology, and pharmaceutical companies. Other factors contributing to the growth of the market in this region include an aging population, as well as increasing incidences of infectious diseases in the region such as HIV and Influenza. For instance, in the US approximately 25,000 people died from the disease during the flu season in 2019-2020.
APAC Market Statistics
The Pharmaceutical Microbiology Market in the Asia Pacific region is anticipated to hold a share of 28% during the foreseen period. The rapid growth of economies in Asia Pacific countries has led to increased expenditure on health care, which is driving demand for pharmaceutical products. Moreover, the growth of the market in the region is driven by growing investments in biotechnology and increasing demand for biologics. Moreover, factors such as the availability of skilled labor and supportive regulatory environments have made this region a key hub for pharmaceutical manufacturing activities.
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?